New York, January 9, 2026, 15:59 (EST) — Regular session
- TG Therapeutics shares fell about 7% in late U.S. trading, after giving up an early lift.
- The company’s CEO is due to present at the J.P. Morgan Healthcare Conference on Jan. 13.
- Traders are looking for fresh signposts on Briumvi demand and 2026 priorities.
TG Therapeutics (TGTX.O) shares fell about 7% on Friday, reversing an early rise and leaving the biotech near its session low. The stock was down 7% at $28.35 by 3:55 p.m. EST after opening at $30.69 and sliding as low as $28.215. It hit $30.83 earlier in the session.
The move comes with the J.P. Morgan Healthcare Conference set to kick off on Monday in San Francisco, a meeting that often pulls in fresh corporate updates and deal chatter in one tight week. The bank’s agenda shows the event runs Jan. 12–15 at the Westin St. Francis.
That matters for stocks like TG because small and mid-cap biotechs can reprice quickly on a slim bit of new detail — or on the lack of it. “We have seen deals get approved in the last year,” Jeremy Meilman, JPMorgan’s global co-head of healthcare investment banking, told Reuters. (Reuters)
TG said on Wednesday that Chairman and CEO Michael S. Weiss will present at the conference on Tuesday, Jan. 13, at 1:30 p.m. Pacific time, with a live webcast and replay available through the company’s investor site. (GlobeNewswire)
The company sells Briumvi, an infused treatment for relapsing forms of multiple sclerosis. Briumvi is an anti-CD20 antibody — a protein drug that targets B cells, part of the immune system — and TG also has earlier-stage programs including a BTK inhibitor, aimed at blocking an enzyme tied to immune signaling.
Friday’s slide pushed the shares back below $30 after they traded above that mark for much of the morning. Traders often treat the day’s low near $28 as the first line to watch; a close that sticks near there can change the mood fast.
But the conference can cut both ways. If management’s remarks point to slower uptake, tighter insurer coverage or heavier competition from bigger multiple sclerosis franchises such as Roche’s Ocrevus or Novartis’s Kesimpta, the stock could stay on the defensive.
